{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:59:10Z","timestamp":1789793950971,"version":"4.0.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn\u2019s disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108\u2009mg every other week (EOW) when the drug was intensified. The primary outcome was steroid-free clinical response (SFCr) defined by at least 50% of PRO2 improvement, no treatment change, no surgery, and SC VDZ persistence at 3\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 154 included patients (66% UC, 34% CD), prior anti-tumor necrosis factor (anti-TNF) exposure was reported in 85% of CD and 50% of UC patients. SC VDZ was intensified for an incomplete response in 73% of CD and 53% of UC patients, mostly at 108\u2009mg weekly (95%). At 3\u2009months, SFCr was achieved in 35% of CD and 43% of UC patients. In multivariate analysis, factors associated with response were secondary loss of response in CD, and prior anti-TNF exposure in UC. At 12\u2009months, 51% of CD and 37% of UC patients maintained SC VDZ. Adverse events occurred in 10 patients including one severe pneumonia and one angioedema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world study evaluating SC VDZ intensification, an SFCr was observed in at least one-third of IBD patients at 3\u2009months, suggesting the benefit of this strategy in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf166","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:54:54Z","timestamp":1757073294000},"source":"Crossref","is-referenced-by-count":2,"title":["Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-6067","authenticated-orcid":false,"given":"Pauline","family":"Wils","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2 , Lille,","place":["France"]},{"name":"Inserm, CHU Lille, U1286- INFINITE- Institute for Translational Research in Inflammation, University of Lille , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Hepato-gastroenterology Department, CHU Montpellier , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[{"name":"Inserm, CHU Clermont-Ferrand, 3iHP, Service d\u2018H\u00e9pato-Gastro Ent\u00e9rologie, Universit\u00e9 Clermont Auvergne , Clermont-Ferrand,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Besan\u00e7on, INSERM Right 1098, Universit\u00e9 Marie et Louis Pasteur , Franche-Comt\u00e9,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Gastroenterology Department CHU Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard Lyon 1, INSERM U1111\u2014CIRI , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, \u201cNutrition, Inflammation and Microbiota-Gut-Brain Axis\u201d, CHU Rouen , Rouen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-2902","authenticated-orcid":false,"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, University Hospital of Amiens and Peritox, Universit\u00e9 de Picardie Jules Verne , Amiens,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[{"name":"University Hospital of Rennes Hepato-gastroenterology Department, , Rennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Guillo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), Aix-Marseille University , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Caron","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Duveau","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Centre Hospitalier de Roubaix ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stefanescu","sequence":"additional","affiliation":[{"name":"Paris IBD Center, Groupe Hospitalier Priv\u00e9 Ambroise Pare-Hartmann , Neuilly,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Bichat-Claude Bernard University Hospital, APHP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-4350","authenticated-orcid":false,"given":"Catherine","family":"Reenaers","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, CHU Li\u00e8ge , Li\u00e8ge,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Gilletta","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, University Hospital of Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[{"name":"Paris Est Cr\u00e9teil University UPEC, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Henri Mondor Hospital, Gastroenterology Department, F\u00e9d\u00e9ration Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs , Cr\u00e9teil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Arab","sequence":"additional","affiliation":[{"name":"University Hospital of Nice Hepato-gastroenterology Department, , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Centre Medico-Chirurgical Magellan, H\u00f4pital Haut-L\u00e9v\u00eaque, Gastroenterology Department, Universit\u00e9 de Bordeaux; INSERM CIC 1401 , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Vidon","sequence":"additional","affiliation":[{"name":"Departement of Gastroenterology, H\u00f4pital Intercommunal de Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aurelien","family":"Amiot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hopitaux Universitaires Bic\u00eatre, AP-HP, Universit\u00e9 Paris Saclay, INSERM CESP , Le Kremlin Bic\u00eatre,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Le Berre","sequence":"additional","affiliation":[{"name":"Institut des Maladies de l\u2019Appareil Digestif (IMAD), H\u00e9pato-Gastro-Ent\u00e9rologie et Assistance Nutritionnelle, Inserm CIC 1413, Nantes Universit\u00e9, CHU Nantes , Nantes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, FORECAST, AP-HP, Saint-Antoine Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dewit","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain (UCLouvain) , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of HepatoGastroenterology, Institut Mutualiste Montsouris , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Goutorbe","sequence":"additional","affiliation":[{"name":"Department of HepatoGastroenterology, Cote Basque Hospital , Bayonne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-8557","authenticated-orcid":false,"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Department of Methodology, Unit\u00e9 de Recherche Clinique Lariboisi\u00e8re Saint-Louis\u2014URC, APHP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Groupe d\u2018Etude Th\u00e9rapeutique des Affections Inflammatoires du Tube Digestif (GETAID)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2025102819152875700_jjaf166-B1","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","author":"Stoner","year":"2014","journal-title":"Patient"},{"key":"2025102819152875700_jjaf166-B2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/MIB.0000000000001140","article-title":"Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease","volume":"23","author":"Buisson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152875700_jjaf166-B3","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2025102819152875700_jjaf166-B4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2025102819152875700_jjaf166-B5","doi-asserted-by":"crossref","first-page":"jjaa177","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of ustekinumab intensification at 90 mg every four weeks in Crohn\u2019s disease: a multicenter study","volume":"15","author":"Fumery","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025102819152875700_jjaf166-B6","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"2025102819152875700_jjaf166-B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102819152875700_jjaf166-B8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102819152875700_jjaf166-B9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2025102819152875700_jjaf166-B10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819152875700_jjaf166-B11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819152875700_jjaf166-B12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/flgastro-2019-101259","article-title":"Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response","volume":"11","author":"Samaan","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"2025102819152875700_jjaf166-B13","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and management of loss of response to vedolizumab in inflammatory bowel disease","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152875700_jjaf166-B14","doi-asserted-by":"crossref","first-page":"otad034","DOI":"10.1093\/crocol\/otad034","article-title":"Practical primer addressing real-world use scenarios of subcutaneous vedolizumab in ulcerative colitis and crohn\u2019s disease: post hoc analyses of VISIBLE studies","volume":"5","author":"Sandborn","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2025102819152875700_jjaf166-B15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn\u2019s disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"key":"2025102819152875700_jjaf166-B16","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ibd\/izad166","article-title":"Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: a multicenter study from the United Kingdom","volume":"30","author":"Lim","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152875700_jjaf166-B17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/apt.15609","article-title":"A clinical decision support tool may help to optimise vedolizumab therapy in Crohn\u2019s disease","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819152875700_jjaf166-B18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819152875700_jjaf166-B19","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819152875700_jjaf166-B20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.029","article-title":"ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse","volume":"22","author":"Jairath","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819152875700_jjaf166-B21","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/ecco-jcc\/jjae190.0009","article-title":"OP09 Dose intensification of vedolizumab is not effective in inducing endoscopic response in Crohn\u2019s disease patients with endoscopic primary non-response","volume":"19","author":"Oldenburg","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025102819152875700_jjaf166-B22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152875700_jjaf166-B23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure\u2013response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study","volume":"56","author":"Vande Casteele","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf166\/64237139\/jjaf166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf166\/64237139\/jjaf166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf166\/64237139\/jjaf166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:15:35Z","timestamp":1761693335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf166\/8250685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf166","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]},"article-number":"jjaf166"}}